NYSE$BMY
Bristol-Myers Squibb Co · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported a slight revenue increase driven by in-line and new products, offset by Revlimid decline, and strengthened growth profile through strategic transactions.
Bristol Myers Squibb reported Q4 2023 revenues of $11.5 billion, a 1% increase year-over-year. GAAP EPS was $0.87, while non-GAAP EPS reached $1.70. The company's in-line and new product portfolio saw a 9% revenue increase, reaching $9.8 billion. Strategic acquisitions and collaborations, including Karuna Therapeutics, RayzeBio, and SystImmune, were announced to bolster long-term growth.
- Fourth-quarter revenues reached $11.5 billion, with GAAP EPS at $0.87 and non-GAAP EPS at $1.70.
- In-line and new product portfolio revenues increased by 9% to $9.8 billion.
- Strategic transactions, including acquisitions of Karuna Therapeutics and RayzeBio, and a collaboration with SystImmune, were initiated.
- 2024 guidance forecasts low single-digit revenue growth and a non-GAAP EPS range of $7.10 to $7.40.
Headline financials
Revenue & EPS history
Bristol-Myers Squibb · Revenue · Quarterly
$11.5B
Forward guidance
Bristol Myers Squibb anticipates low single-digit revenue growth and a non-GAAP EPS range of $7.10 to $7.40 for 2024.
Tailwinds
- Total 2024 revenues are expected to increase by low single-digits.
- Excluding foreign exchange, total revenues are expected to increase by low single-digits.
- Non-GAAP Gross margin is expected to be approximately 74%.
- Other Income/(Expense) is expected to be approximately $250 million.
- An effective tax rate of approximately 17.5%.
Headwinds
- The 2024 financial guidance excludes the impact of any potential future strategic acquisitions, including the announced planned acquisitions of RayzeBio and Karuna.
- Guidance excludes divestitures, specified items, and the impact of future Acquired IPRD charges.
- The company is not, without unreasonable effort, able to reliably predict the impact of accelerated depreciation and impairment charges.
- The company is not, without unreasonable effort, able to reliably predict legal and other settlements.
- The company is not, without unreasonable effort, able to reliably predict gains and losses from equity investments and other adjustments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.1%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+0.9%
Avg return
30 days after
47%
34 / 73 earnings
Positive
+8.2%
Q2 2024
Best reaction
-9.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | -1.1% | -0.7% | |
| Q4 2025 | +3.3% | +5.6% | +4.6% | |
| Q3 2025 | +7.1% | +7.0% | +15.5% | |
| Q2 2025 | -5.8% | -0.3% | +2.6% | |
| Q1 2025 | +0.4% | +1.4% | -3.5% | |
| Q4 2024 | -3.8% | -6.3% | +2.3% | |
| Q3 2024 | +3.2% | +6.2% | +12.5% | |
| Q2 2024 | +8.2% | +5.1% | +6.3% | |
| Q1 2024 | -8.2% | -10.1% | -15.6% | |
| Q4 2023 | -1.4% | -0.1% | +4.6% | |
| Q3 2023 | -9.9% | -9.0% | -12.1% | |
| Q2 2023 | -3.2% | -3.0% | -2.1% | |
| Q1 2023 | -1.8% | +0.1% | -6.2% | |
| Q4 2022 | +4.5% | +4.6% | -2.7% | |
| Q3 2022 | +2.0% | +5.3% | +8.4% | |
| Q2 2022 | +1.5% | -0.0% | -3.3% | |
| Q1 2022 | -2.7% | -1.2% | -1.4% | |
| Q4 2021 | +3.3% | +4.8% | +8.3% | |
| Q3 2021 | -1.9% | +0.8% | -2.9% | |
| Q2 2021 | +1.0% | +0.8% | -1.3% | |
| Q1 2021 | -5.5% | -3.2% | -0.5% | |
| Q4 2020 | -1.8% | -3.7% | -2.6% | |
| Q3 2020 | -2.5% | -1.4% | -4.8% | |
| Q2 2020 | +2.2% | +5.8% | +0.4% | |
| Q1 2020 | -0.1% | +3.6% | +0.3% | |
| Q4 2019 | +1.0% | +2.1% | -8.1% | |
| Q3 2019 | +0.5% | -0.8% | +0.1% | |
| Q2 2019 | +5.0% | +3.1% | +7.7% | |
| Q1 2019 | +2.8% | +4.1% | +4.9% | |
| Q4 2018 | -2.1% | -3.3% | +2.0% | |
| Q3 2018 | +3.3% | +2.4% | +8.4% | |
| Q2 2018 | -3.6% | -0.5% | +1.6% | |
| Q1 2018 | +1.0% | +1.8% | +2.0% | |
| Q4 2017 | -4.1% | -1.2% | +4.1% | |
| Q3 2017 | -6.3% | -3.7% | -4.0% | |
| Q2 2017 | -1.3% | +0.2% | +4.3% | |
| Q1 2017 | +4.2% | +4.1% | +0.4% | |
| Q4 2016 | -3.7% | -0.8% | +13.9% | |
| Q3 2016 | +3.5% | +3.1% | +15.6% | |
| Q2 2016 | -2.2% | -1.9% | -23.1% | |
| Q1 2016 | +2.8% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +4.7% | — | — | |
| Q2 2015 | -4.9% | — | — | |
| Q1 2015 | -1.3% | — | — | |
| Q4 2014 | -1.8% | — | — | |
| Q3 2014 | +2.0% | — | — | |
| Q2 2014 | +0.1% | — | — | |
| Q1 2014 | -0.5% | — | — | |
| Q4 2013 | -7.8% | — | — | |
| Q3 2013 | -0.7% | — | — | |
| Q2 2013 | -0.8% | — | — | |
| Q1 2013 | -2.8% | — | — | |
| Q4 2012 | +5.1% | — | — | |
| Q3 2012 | +1.5% | — | — | |
| Q2 2012 | +3.1% | — | — | |
| Q1 2012 | -0.6% | — | — | |
| Q4 2011 | +0.9% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q2 2011 | +0.2% | — | — | |
| Q1 2011 | -0.0% | — | — | |
| Q4 2010 | -1.5% | — | — | |
| Q4 2007 | -1.5% | — | — | |
| Q3 2010 | -1.1% | — | — | |
| Q2 2010 | -0.4% | — | — | |
| Q1 2009 | +4.0% | — | — | |
| Q1 2010 | +0.7% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q3 2008 | -2.0% | — | — | |
| Q3 2009 | -2.0% | — | — | |
| Q4 2008 | +5.5% | — | — | |
| Q2 2008 | +5.5% | — | — | |
| Q2 2009 | +5.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro